Natural killer cell biology: An update and future directions

Fauriat, 2010, Regulation of human NK-cell cytokine and chemokine production by target cell recognition, Blood, 115, 2167, 10.1182/blood-2009-08-238469 Vivier, 2008, Functions of natural killer cells, Nat Immunol, 9, 503, 10.1038/ni1582 Waggoner, 2012, Natural killer cells act as rheostats modulating antiviral T cells, Nature, 481, 394, 10.1038/nature10624 Schuster, 2012, Crosstalk between neutrophils and dendritic cells: a context-dependent process, J Leukoc Biol Wehner, 2011, The bidirectional crosstalk between human dendritic cells and natural killer cells, J Innate Immun, 3, 258, 10.1159/000323923 Spits, 2013, Innate lymphoid cells—a proposal for uniform nomenclature, Nat Rev Immunol, 13, 145, 10.1038/nri3365 Walker, 2013, Innate lymphoid cells—how did we miss them?, Nat Rev Immunol, 13, 75, 10.1038/nri3349 Caligiuri, 2008, Human natural killer cells, Blood, 112, 461, 10.1182/blood-2007-09-077438 Fehniger, 2003, CD56bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL-2: a potential new link between adaptive and innate immunity, Blood, 101, 3052, 10.1182/blood-2002-09-2876 Martin-Fontecha, 2004, Induced recruitment of NK cells to lymph nodes provides IFN-gamma for TH1 priming, Nat Immunol, 5, 1260, 10.1038/ni1138 Fang, 2010, Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking, J Exp Med, 207, 2369, 10.1084/jem.20100282 De Maria, 2011, Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-gamma on activation, Proc Natl Acad Sci U S A, 108, 728, 10.1073/pnas.1012356108 Korbel, 2009, Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals, J Immunol, 182, 6426, 10.4049/jimmunol.0804224 Zhang, 2011, Natural killer cell-triggered vascular transformation: maternal care before birth?, Cell Mol Immunol, 8, 1, 10.1038/cmi.2010.38 Orange, 2006, Human natural killer cell deficiencies, Curr Opin Allergy Clin Immunol, 6, 399, 10.1097/ACI.0b013e3280106b65 Ljunggren, 1990, In search of the “missing self”: MHC molecules and NK cell recognition, Immunol Today, 11, 237, 10.1016/0167-5699(90)90097-S Horst, 2011, Viral evasion of T cell immunity: ancient mechanisms offering new applications, Curr Opin Immunol, 23, 96, 10.1016/j.coi.2010.11.005 Seliger, 2006, Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation, Int J Cancer, 118, 129, 10.1002/ijc.21312 Krzewski, 2012, Human NK cell lytic granules and regulation of their exocytosis, Front Immunol, 3, 335, 10.3389/fimmu.2012.00335 MacFarlane, 2006, Signal transduction in natural killer cells, Curr Top Microbiol Immunol, 298, 23 Cichocki, 2010, Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-Like RNA in human NK Cells, J Immunol, 185, 2009, 10.4049/jimmunol.1000855 Davies, 2007, Identification of bidirectional promoters in the human KIR genes, Genes Immun, 8, 245, 10.1038/sj.gene.6364381 Saleh, 2004, Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation, Immunity, 21, 55, 10.1016/j.immuni.2004.06.005 Parham, 2005, MHC class I molecules and KIRs in human history, health and survival, Nat Rev Immunol, 5, 201, 10.1038/nri1570 Anderson, 2001, The ever-expanding Ly49 gene family: repertoire and signaling, Immunol Rev, 181, 79, 10.1034/j.1600-065X.2001.1810106.x Vilches, 2002, KIR: diverse, rapidly evolving receptors of innate and adaptive immunity, Annu Rev Immunol, 20, 217, 10.1146/annurev.immunol.20.092501.134942 Lanier, 2008, Up on the tightrope: natural killer cell activation and inhibition, Nat Immunol, 9, 495, 10.1038/ni1581 Moretta, 2001, Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis, Ann Rev Immunol, 19, 197, 10.1146/annurev.immunol.19.1.197 Bauer, 1999, Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA, Science, 285, 727, 10.1126/science.285.5428.727 Brandt, 2009, The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans, J Exp Med, 206, 1495, 10.1084/jem.20090681 Brown, 2012, Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins, Blood, 120, 3729, 10.1182/blood-2012-05-429977 Gross, 2010, Tethering of intercellular adhesion molecule on target cells is required for LFA-1–dependent NK cell adhesion and granule polarization, J Immunol, 185, 2918, 10.4049/jimmunol.1000761 Mace, 2010, Elucidation of the integrin LFA-1–mediated signaling pathway of actin polarization in natural killer cells, Blood, 116, 1272, 10.1182/blood-2009-12-261487 Hanke, 2001, MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model, Eur J Immunol, 31, 3370, 10.1002/1521-4141(200111)31:11<3370::AID-IMMU3370>3.0.CO;2-2 Schönberg, 2011, Analyses of HLA-C–specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition, Blood, 117, 98, 10.1182/blood-2010-03-273656 Anfossi, 2006, Human NK cell education by inhibitory receptors for MHC class I, Immunity, 25, 331, 10.1016/j.immuni.2006.06.013 Brodin, 2009, The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells, Blood, 113, 2434, 10.1182/blood-2008-05-156836 Cooley, 2007, A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature, Blood, 110, 578, 10.1182/blood-2006-07-036228 Kim, 2008, HLA alleles determine differences in human natural killer cell responsiveness and potency, Proc Natl Acad Sci U S A, 105, 3053, 10.1073/pnas.0712229105 Raulet, 2006, Self-tolerance of natural killer cells, Nat Rev Immunol, 6, 520, 10.1038/nri1863 Fernandez, 2005, A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules, Blood, 105, 4416, 10.1182/blood-2004-08-3156 Kim, 2005, Licensing of natural killer cells by host major histocompatibility complex class I molecules, Nature, 436, 709, 10.1038/nature03847 Raulet, 1997, Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors, Immunol Rev, 155, 41, 10.1111/j.1600-065X.1997.tb00938.x Valiante, 1997, Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors, Immunity, 7, 739, 10.1016/S1074-7613(00)80393-3 Furukawa, 1999, Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I), Hum Immunol, 60, 32, 10.1016/S0198-8859(98)00097-4 Liao, 1991, MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity, Science, 253, 199, 10.1126/science.1853205 Brodin, 2009, NK cell education: not an on-off switch but a tunable rheostat, Trends Immunol, 30, 143, 10.1016/j.it.2009.01.006 Joncker, 2009, NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model, J Immunol, 182, 4572, 10.4049/jimmunol.0803900 Chalifour, 2009, A Role for cis interaction between the inhibitory Ly49A receptor and MHC class I for natural killer cell education, Immunity, 30, 337, 10.1016/j.immuni.2008.12.019 Orr, 2010, 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection, Nat Immunol, 11, 321, 10.1038/ni.1849 Koka, 2003, Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice, J Exp Med, 197, 977, 10.1084/jem.20021836 Jamieson, 2004, Turnover and proliferation of NK cells in steady state and lymphopenic conditions, J Immunol, 172, 864, 10.4049/jimmunol.172.2.864 Prlic, 2003, In vivo survival and homeostatic proliferation of natural killer cells, J Exp Med, 197, 967, 10.1084/jem.20021847 Sun, 2011, Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection, J Exp Med, 208, 357, 10.1084/jem.20100479 Sun, 2009, Adaptive immune features of natural killer cells, Nature, 457, 557, 10.1038/nature07665 Hayakawa, 2006, CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity, J Immunol, 176, 1517, 10.4049/jimmunol.176.3.1517 Sun, 2012, Proinflammatory cytokine signaling required for the generation of natural killer cell memory, J Exp Med, 209, 947, 10.1084/jem.20111760 Foley, 2012, Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function, Blood, 119, 2665, 10.1182/blood-2011-10-386995 Lopez-Verges, 2011, Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection, Proc Natl Acad Sci U S A, 108, 14725, 10.1073/pnas.1110900108 Beziat, 2013, NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs, Blood, 121, 2678, 10.1182/blood-2012-10-459545 Björkström, 2011, Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus, J Exp Med, 208, 13, 10.1084/jem.20100762 Cooper, 2009, Cytokine-induced memory-like natural killer cells, Proc Natl Acad Sci U S A, 106, 1915, 10.1073/pnas.0813192106 Ni, 2012, Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors, J Exp Med, 209, 2351, 10.1084/jem.20120944 Romee, 2012, Cytokine activation induces human memory-like NK cells, Blood, 120, 4751, 10.1182/blood-2012-04-419283 O'Leary, 2006, T cell- and B cell-independent adaptive immunity mediated by natural killer cells, Nat Immunol, 7, 507, 10.1038/ni1332 Paust, 2010, Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses, Nat Immunol, 11, 1127, 10.1038/ni.1953 Seidel, 2013, Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies, Front Immunol, 4, 76, 10.3389/fimmu.2013.00076 Kohrt, 2011, CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies, Blood, 117, 2423, 10.1182/blood-2010-08-301945 Benson, 2010, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody, Blood, 116, 2286, 10.1182/blood-2010-02-271874 Binyamin, 2008, Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy, J Immunol, 180, 6392, 10.4049/jimmunol.180.9.6392 Sola, 2009, Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo, Proc Natl Acad Sci U S A, 106, 12879, 10.1073/pnas.0901653106 Romagne, 2009, Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells, Blood, 114, 2667, 10.1182/blood-2009-02-206532 Benson, 2012, A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma, Blood, 120, 4324, 10.1182/blood-2012-06-438028 Vey, 2012, A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, 120, 4317, 10.1182/blood-2012-06-437558 Benson, 2011, IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect, Blood, 118, 6387, 10.1182/blood-2011-06-360255 Khakoo, 2004, HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection, Science, 305, 872, 10.1126/science.1097670 Hiby, 2004, Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success, J Exp Med, 200, 957, 10.1084/jem.20041214 O'Connor, 2011, Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1, J Immunol, 187, 2162, 10.4049/jimmunol.1002906 Vivian, 2011, Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B, Nature, 479, 401, 10.1038/nature10517 Martin, 2002, Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS, Nat Genet, 31, 429, 10.1038/ng934 Martin, 2007, Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1, Nat Genet, 39, 733, 10.1038/ng2035 Pelak, 2011, Copy number variation of KIR genes influences HIV-1 control, PLoS Biol, 9, e1001208, 10.1371/journal.pbio.1001208 Velardi, 2002, Alessandro, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol, 23, 438, 10.1016/S1471-4906(02)02284-6 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Ruggeri, 1999, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, Blood, 94, 333, 10.1182/blood.V94.1.333.413a31_333_339 Miller, 2007, Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT, Blood, 109, 5058, 10.1182/blood-2007-01-065383 Hsu, 2007, Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component, Tissue Antigens, 69, 42, 10.1111/j.1399-0039.2006.759_5.x McQueen, 2007, Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation, Hum Immunol, 68, 309, 10.1016/j.humimm.2007.01.019 Cooley, 2010, Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia, Blood, 116, 2411, 10.1182/blood-2010-05-283051 Stringaris, 2010, Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies, Biol Blood Marrow Transplant, 16, 1257, 10.1016/j.bbmt.2010.03.004 Venstrom, 2012, HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1, N Engl J Med, 367, 805, 10.1056/NEJMoa1200503 Haas, 2011, NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation, Blood, 117, 1021, 10.1182/blood-2010-02-269381 Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974 Rubnitz, 2010, NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J Clin Oncol, 28, 955, 10.1200/JCO.2009.24.4590 Curti, 2011, Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients, Blood, 118, 3273, 10.1182/blood-2011-01-329508 Koepsell, 2013, Natural killer cells: a review of manufacturing and clinical utility, Transfusion, 53, 404, 10.1111/j.1537-2995.2012.03724.x Klingemann, 2013, Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions, Transfusion, 53, 412, 10.1111/j.1537-2995.2012.03764.x Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540 Altvater, 2009, 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells, Clin Cancer Res, 15, 4857, 10.1158/1078-0432.CCR-08-2810 Imai, 2005, Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells, Blood, 106, 376, 10.1182/blood-2004-12-4797 Li, 2010, Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method, Cancer Gene Ther, 17, 147, 10.1038/cgt.2009.61 Uherek, 2002, Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction, Blood, 100, 1265, 10.1182/blood.V100.4.1265.h81602001265_1265_1273 Muller, 2008, Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells, Cancer Immunol Immunother, 57, 411, 10.1007/s00262-007-0383-3 Arai, 2008, Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial, Cytotherapy, 10, 625, 10.1080/14653240802301872 McDaniel, 2012, Molecular action of lenalidomide in lymphocytes and hematologic malignancies, Adv Hematol, 2012, 513702, 10.1155/2012/513702 Zhu, 2008, Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation, Cancer Immunol Immunother, 57, 1849, 10.1007/s00262-008-0512-7 Hayashi, 2005, Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application, Br J Haematol, 128, 192, 10.1111/j.1365-2141.2004.05286.x Hsu, 2011, The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy, Blood, 117, 1605, 10.1182/blood-2010-04-278432 Chen, 2011, Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives, Curr Cancer Drug Targets, 11, 239, 10.2174/156800911794519752 Armeanu, 2008, Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma, Clin Cancer Res, 14, 3520, 10.1158/1078-0432.CCR-07-4744 Krieg, 2012, Novel immune modulators used in hematology: impact on NK cells, Front Immunol, 3, 388 Lundqvist, 2009, Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells, Blood, 113, 6120, 10.1182/blood-2008-11-190421 Lundqvist, 2011, Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells, J Cancer, 2, 383, 10.7150/jca.2.383